DNA Repair Deficiencies and the Promise of PARP Inhibition in Prostate Cancer: Clinical Implications

In this online educational program, CCO’s expert faculty explore optimal care for patients with prostate cancer, focusing on DNA repair deficiencies, genetic testing, and best practice for the use of PARP inhibitors.
Johann Sebastian de Bono, MB, ChB, FRCP, MSc, PhD
Program Director
William B. Isaacs, PhD
Todd M. Morgan, MD

Downloadable Slidesets

In this downloadable slideset, William B. Isaacs, PhD, reviews DNA repair deficiencies in prostate cancer and their therapeutic implications.

William B. Isaacs, PhD Released: May 25, 2018

In this downloadable slideset, Todd M. Morgan, MD, provides practical guidance on somatic and germline testing in prostate cancer, including rationale, who to test, how to test, and implications for screening/early detection and localized disease. 

Todd M. Morgan, MD Released: May 25, 2018

In this downloadable slideset, Johann Sebastian de Bono, MB, ChB, FRCP, MSc, PhD, reviews the available clinical data on PARP inhibitors in advanced prostate cancer and explores how these agents may affect management strategies for patients in the near future.

Johann Sebastian de Bono, MB, ChB, FRCP, MSc, PhD
Program Director
Released: May 25, 2018
Jointly provided by Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

This activity is supported by an educational grant from
AstraZeneca

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue